



OSMM&N File No. 0660-0158-0 PCT

Dept.: Chemical

By: NFO/TMC/krs

Serial No. 09/367,703

In the matter of the Application of: Catherine ROUGEOT, et al.

For: THERAPEUTIC USE OF THE SMRI PROTEIN AND ACTIVE
DERIVATIVES THEREOF

Due Date: n/a

The following has been received in the U.S. Patent Office on the date stamped hereon:

- Dep. Acct. Order Form
- PTO Cover Letter
- Sequence Listing (Paper; 7 pp.)
- Computer-Readable Sequence Listing (Diskette)
- Statement

COPY

RECEIVED
TECH CENTER 1500/22900
02 NOV - 6 AM 9:24

Docket No.: 0660-0158-0 PCT



OBLON
SPIVAK
McCLELLAND
MAIER
&
NEUSTADT
P.C.

ATTORNEYS AT LAW

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

RE: Application Serial No.: 09/367,703
Applicants: Catherine ROUGEOT, et al.
Filing Date: October 13, 1999
For: THERAPEUTIC USE OF THE SMR1 PROTEIN AND
ACTIVE DERIVATIVES THEREOF
Group Art Unit: 1642
Examiner: K. Canella

SIR:

Attached hereto for filing are the following papers:

Sequence Listing (Paper; 7 pp.); Computer-Readable Sequence Listing (Diskette); Statement

Our check in the amount of \$0.00 is attached covering any required fees. In the event any variance exists between the amount enclosed and the Patent Office charges for filing the above-noted documents, including any fees required under 37 C.F.R. 1.136 for any necessary Extension of Time to make the filing of the attached documents timely, please charge or credit the difference to our Deposit Account No. 15-0030. Further, if these papers are not considered timely filed, then a petition is hereby made under 37 C.F.R. 1.136 for the necessary extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.



22850

(703) 413-3000 (phone)
(703) 413-2220 (fax)

Norman F. Oblon
Registration No. 24,618

Thomas M. Cunningham
Registration No. 45,394

COPY

Docket No. 240156US01DIV

IN RE APPLICATION OF: Catherine ROUGEOT, et al.

SERIAL NO: 10/620,462

FILED: July 17, 2003

FOR: THERAPEUTIC USE OF THE SMR1 PROTEIN AND ACTIVE DERIVATIVES THEREOF



COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

SIR:

Transmitted herewith is a supplemental preliminary amendment in the above-identified application.

- ☐ No additional fee is required
- ☐ Small entity status of this application under 37 C.F.R. §1.9 and §1.27 is claimed.
- ☒ Additional documents filed herewith: Statement Regarding Sequence Listing; Substitute Specification (79 pp.); Copy of Receipt Card (filed 11-6-02); Copy of PTO Cover Letter (filed 11-6-02); Copy of Statement Under 37 C.F.R. 1.821(F)-(G) (filed 11-6-02); Copy of Sequence Listing (filed 11-6-02)

The Fee has been calculated as shown below:

CLAIMS	CLAIMS REMAINING		HIGHEST NUMBER PREVIOUSLY PAID	NO. EXTRA CLAIMS	RATE	CALCULATIONS
TOTAL	27	MINUS	27	0	x \$18 =	\$0.00
INDEPENDENT	3	MINUS	3	0	x \$84 =	\$0.00
		<input type="checkbox"/> MULTIPLE DEPENDENT CLAIMS			+ \$280 =	\$0.00
		TOTAL OF ABOVE CALCULATIONS				\$0.00
		<input type="checkbox"/> Reduction by 50% for filing by Small Entity				\$0.00
		<input type="checkbox"/> Recordation of Assignment			+ \$40 =	\$0.00
		TOTAL				\$0.00

- ☐ A check in the amount of \$0.00 is attached.
- ☐ Credit card payment form is attached to cover the fees in the amount of \$0.00
- ☒ Please charge any additional Fees for the papers being filed herewith and for which no check or credit card payment form is enclosed herewith, or credit any overpayment to deposit Account No. 15-0030. A duplicate copy of this sheet is enclosed.
- ☒ If these papers are not considered timely filed by the Patent and Trademark Office, then a petition is hereby made under 37 C.F.R. §1.136, and any additional fees required under 37 C.F.R. §1.136 for any necessary extension of time may be charged to Deposit Account No. 15-0030. A duplicate copy of this sheet is enclosed.

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.


Norman F. Oblon

Registration No. 24,618

Customer Number

22850

Tel. (703) 413-3000
Fax. (703) 413-2220
(OSMMN 05/03)

Thomas M. Cunningham
Registration No. 45,394